Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) ...

IB-T101, a CD70-targeted chimeric antigen receptor therapy, is being studied for relapsed clear cell renal cell carcinoma ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S.

The collaboration will drive cord blood-derived allogeneic CAR T-cell development. Singapore General Hospital (SGH) has ...

Then games like Halls of Torment bolted on a bit more ARPG stuff—things got slightly more measured, predictable, and I lost ...

This roundup highlights a common drug that can help treat multiple myeloma, a paper analyzing the benefit of a colorectal surgery follow-up test ...

Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment ...

Anixa Biosciences (ANIX) announced has it has dosed its final patient in the third cohort of its ongoing Phase 1 clinical trial evaluating its ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced has it has dosed its final patient in the ...

City of Hope® Research Spotlight offers a glimpse at groundbreaking scientific and clinical discoveries advancing lifesaving cures for patients with cancer, diabetes and other chronic, ...

Manipulating the immune system to treat cancer has generated phenomenal responses in some patients, including complete cures, ...